OCX vs. DRRX, CDIO, AWH, TRIB, ACHL, BMRA, ICCC, ABIO, VNRX, and IFRX Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include DURECT (DRRX), Cardio Diagnostics (CDIO), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Achilles Therapeutics (ACHL), Biomerica (BMRA), ImmuCell (ICCC), ARCA biopharma (ABIO), VolitionRx (VNRX), and InflaRx (IFRX). These companies are all part of the "medical" sector.
DURECT (NASDAQ:DRRX ) and OncoCyte (NASDAQ:OCX ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
Do analysts rate DRRX or OCX?
DURECT currently has a consensus price target of $27.50, suggesting a potential upside of 2,825.22%. OncoCyte has a consensus price target of $4.06, suggesting a potential upside of 37.25%. Given OncoCyte's stronger consensus rating and higher possible upside, analysts plainly believe DURECT is more favorable than OncoCyte.
Is DRRX or OCX more profitable?
DURECT has a net margin of -279.77% compared to DURECT's net margin of -2,905.14%. DURECT's return on equity of -135.45% beat OncoCyte's return on equity.
Which has more risk and volatility, DRRX or OCX?
DURECT has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Does the MarketBeat Community favor DRRX or OCX?
DURECT received 310 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 65.56% of users gave DURECT an outperform vote while only 9.23% of users gave OncoCyte an outperform vote.
Do insiders & institutionals have more ownership in DRRX or OCX?
28.0% of DURECT shares are held by institutional investors. Comparatively, 55.4% of OncoCyte shares are held by institutional investors. 4.3% of DURECT shares are held by company insiders. Comparatively, 1.9% of OncoCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Which has higher earnings and valuation, DRRX or OCX?
DURECT has higher revenue and earnings than OncoCyte.
Does the media favor DRRX or OCX?
In the previous week, DURECT had 8 more articles in the media than OncoCyte. MarketBeat recorded 19 mentions for DURECT and 11 mentions for OncoCyte. OncoCyte's average media sentiment score of 0.34 beat DURECT's score of -0.03 indicating that DURECT is being referred to more favorably in the media.
Summary DURECT beats OncoCyte on 12 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
OncoCyte Competitors List
Related Companies and Tools